Diagnosis and management of spinal muscular atrophy : : Part 2
Abstract: This is the second half of a two-part document updating the standard of care recommendations for spinal muscular atrophy published in 2007. This part includes updated recommendations on pulmonary management and acute care issues, and topics that have emerged in the last few years such as other organ involvement in the severe forms of spinal muscular atrophy and the role of medications. Ethical issues and the choice of palliative versus supportive care are also addressed. These recommendations are becoming increasingly relevant given recent clinical trials and the prospect that commercially available therapies will likely change the survival and natural history of this disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Neuromuscular disorders. - 28, 3 (2018) , 197-207, ISSN: 1873-2364
- Schlagwort
-
Care
Ernährung
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2019
- Urheber
-
Finkel, Richard S.
Mercuri, Eugenio
Meyer, Oscar H.
Simonds, Anita K.
Schroth, Mary K.
Graham, Robert J.
Kirschner, Janbernd
Iannaccone, Susan T.
Crawford, Thomas O.
Woods, Simon
Muntoni, Francesco
Wirth, Brunhilde
Montes, Jacqueline
Main, Marion
Mazzone, Elena S.
Vitale, Michael G.
Snyder, Brian D.
Quijano‐Roy, Susana
Bertini, Enrico
Hurst Davis, R.
Qian, Ying
Sejersen, Thomas
- DOI
-
10.1016/j.nmd.2017.11.004
- URN
-
urn:nbn:de:bsz:25-freidok-1440339
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:52 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Finkel, Richard S.
- Mercuri, Eugenio
- Meyer, Oscar H.
- Simonds, Anita K.
- Schroth, Mary K.
- Graham, Robert J.
- Kirschner, Janbernd
- Iannaccone, Susan T.
- Crawford, Thomas O.
- Woods, Simon
- Muntoni, Francesco
- Wirth, Brunhilde
- Montes, Jacqueline
- Main, Marion
- Mazzone, Elena S.
- Vitale, Michael G.
- Snyder, Brian D.
- Quijano‐Roy, Susana
- Bertini, Enrico
- Hurst Davis, R.
- Qian, Ying
- Sejersen, Thomas
- Universität
Entstanden
- 2019
Ähnliche Objekte (12)
Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study
Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Nusinersen - praktische Aspekte der Therapie bei Spinaler Muskelatrophie im klinischen Allltag
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study
Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Nusinersen - praktische Aspekte der Therapie bei Spinaler Muskelatrophie im klinischen Allltag
2024 update: European consensus statement on gene therapy for spinal muscular atrophy
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Advances in treatment of spinal muscular atrophy – new phenotypes, new challenges, new implications for care
Correction to: Risdiplam inpatients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH study
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the NURTURE study
Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
Combination disease‐modifying treatment in spinal muscular atrophy: a proposed classification
Cathepsin D as biomarker in CSF of nusinersen‐treated patients with spinal muscular atrophy
Nusinersen - praktische Aspekte der Therapie bei Spinaler Muskelatrophie im klinischen Allltag
2024 update: European consensus statement on gene therapy for spinal muscular atrophy